Skyrizi (risankizumab-rzaa) is a medication used to treat adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis and moderately-to-severely active Crohn's disease. Skyrizi is not known to interact with alcohol and there is no warning in the drug’s Product Label against drinking alcohol while receiving Skyrizi. However, people receiving treatment with Skyrizi may benefit from avoid alcohol if it makes the symptoms of their condition worse.